Avelumab Produces Durable Responses in Metastatic Merkel Cell Carcinoma

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video we discuss promising results of the anti–PD-L1 agent avelumab in patients with metastatic Merkel cell carcinoma who had previously been treated with chemotherapy.

The phase II JAVELIN Merkel 200 trial found that the anti–PD-L1 agent avelumab produced durable responses in patients with metastatic Merkel cell carcinoma who had previously been treated with chemotherapy, according to data presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago (abstract 9508).

In this video, Howard L. Kaufman, MD, of the Rutgers Cancer Institute of New Jersey, discusses these results.

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Related Content
Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

RP1/Nivolumab Combo Shows Responses in Advanced Pretreated Melanoma

Ashley Chan
June 8th 2025
Article

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Roman Fabbricatore
June 5th 2025
Article

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Less Inflammatory Diets Associated with Improved OS in Stage III Colon Cancer

Less Inflammatory Diets Associated with Improved OS in Stage III Colon Cancer

Bridget Hoyt
June 3rd 2025
Article

Data suggest that anti-inflammatory diets and regular physical activity are associated with improved overall survival in patients with stage III resected colon cancer.

Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets

Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets

Tim Cortese
June 1st 2025
Article

The combination elicited a clinical benefit rate of 63.0% and an overall response rate of 22.2% in anti–PD-L1–refractory melanoma with melanoma brain metastases.